Astellas dumps a PhIII lung cancer drug; GSK gets one success, one failure in a pair of pivotal Crohn’s trials
→ Japan’s Astellas Pharma is punting its Phase III drug ASP8273, halting the late-stage SOLAR trial evaluating the efficacy and safety of ASP8273 versus …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.